Tsubota Laboratory (TSE:4890) EBIT: 円-760.2 Mil (TTM As of Mar. 2026)


TSE:4890 Tsubota Laboratory Inc TSE:4890
63 GF Score
Price 円221.00
GF Value 円83.95
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Tsubota Laboratory EBIT?

Tsubota Laboratory TSE:4890 -0.45% 63 EBIT is 円-760.2 Mil as of Mar. 2026. GuruFocus rates TSE:4890 with a GF Score™ of 63/100 and a GF Value™ of 円83.95 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Tsubota Laboratory's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was 円-427.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was 円-760.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Tsubota Laboratory's annualized ROC % for the quarter that ended in Mar. 2026 was -204.65%. Tsubota Laboratory's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -2,692.49%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Tsubota Laboratory's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -15.84%.

Tsubota Laboratory  (TSE:4890) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Tsubota Laboratory's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-872.858 * ( 1 - 0% )/( (503.86 + 349.176)/ 2 )
=-872.858/426.518
=-204.65 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1888.497 - 82.704 - ( 1388.066 - max(0, 538.564 - 1840.497+1388.066))
=503.86

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1318.78 - 96.508 - ( 969.849 - max(0, 407.993 - 1281.089+969.849))
=349.176

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Tsubota Laboratory's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-854.878/( ( (36.326 + max(-63.849, 0)) + (27.175 + max(-74.469, 0)) )/ 2 )
=-854.878/( ( 36.326 + 27.175 )/ 2 )
=-854.878/31.7505
=-2,692.49 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(56.345 + 285.5 + 110.586) - (82.704 + 0 + 433.576)
=-63.849

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(14.463 + 188.924 + 107.853) - (96.508 + 0 + 289.201)
=-74.469

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Tsubota Laboratory's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-760.167/4799.905
=-15.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tsubota Laboratory EBIT Related Terms

Tsubota Laboratory EBIT Historical Data

* Premium members only.

The historical data trend for Tsubota Laboratory's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tsubota Laboratory EBIT Chart

Tsubota Laboratory Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial 203.37 145.00 -635.37 282.13 -760.17

Tsubota Laboratory Semi-Annual Data
Mar20 Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -232.09 65.26 216.88 -332.73 -427.44

TSE:4890 vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Tsubota Laboratory's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tsubota Laboratory EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tsubota Laboratory's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Tsubota Laboratory's EV-to-EBIT falls into.


TSE:4890
63GF Score
Tsubota Laboratory Inc TSE:4890
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tsubota Laboratory EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円-760.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of 円-760.2 Mil mean?
Tsubota Laboratory (TSE:4890) has a EBIT of 円-760.2 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Tsubota Laboratory.
Is Tsubota Laboratory's EBIT too high?
Tsubota Laboratory's current EBIT is 円-760.2 Mil. Overall, Tsubota Laboratory has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tsubota Laboratory's EBIT compare to ABT and SYK?
Tsubota Laboratory's EBIT of 円-760.2 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Tsubota Laboratory. Tsubota Laboratory's current EBIT is 円-760.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tsubota Laboratory stock overvalued right now?
Based on GuruFocus' analysis, Tsubota Laboratory (TSE:4890) is currently considered Significantly Overvalued. The stock's GF Value™ is 円83.95, compared to a current price of 円221.00 — trading 163.3% above its estimated fair value. The current EBIT is 円-760.2 Mil. Tsubota Laboratory's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Tsubota Laboratory (TSE:4890), the current EBIT is 円-760.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tsubota Laboratory (TSE:4890) Overvalued in 2026?

Based on GuruFocus' analysis, Tsubota Laboratory stock appears to be overvalued. The current stock price of 円221.00 is trading 163.3% above its estimated GF Value™ of 円83.95. GuruFocus considers Tsubota Laboratory to be Significantly Overvalued.

Key valuation signals for TSE:4890:

  • EBIT: 円-760.2 Mil
  • GF Value™: 円83.95 vs. price of 円221.00 (163.3% above fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the TSE:4890 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tsubota Laboratory Business Description

Address 34 Shinanomachi, 304 Toshin Shinanomachi-ekimae Building, Shinjuku-ku, Tokyo, JPN, 160-0016
Tsubota Laboratory Inc is engaged in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia.
63GF Score

Get the complete analysis for TSE:4890

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円221.00
Price
円83.95
GF Value